PO-0739: Prognostic factors for toxicity in childhood medulloblastoma treated with Helical Tomotherapy  by Raul, M. et al.
  
2nd ESTRO Forum 2013   S279 
Kaplan-Meier curve for individual genotypes against the animal age in 
months. In case of aggressive metastasis or sarcomas, the animals 
were euthanized and the tumours were isolated for analysis. Adult 
Cpt1cgt/gt and wild type mice were individually housed in calorimeter 
cages with ad libitum access to standard chow and water. During 
seven dark/light cycles we measured the respiratory exchange ratio, 
the energy expenditure rate, the food intake and the activity rate.  
Results: A higher survival rate and a lower frequency of tumors were 
observed in the Nf1+/-:p53+/-:Cpt1cgt/gt mice if compared with the 
Nf1+/-:p53+/- group. Nf1+/-:p53+/-:Cpt1cgt/gt mice were leaner than the 
Cpt1cgt/gt, the Nf1+/-:p53+/- and the WT control mice. Interestingly, 
rather than developing tumors, 28% of the Nf1+/-:p53+/-:Cpt1cgt/gt died 
due to cachexia, muscle fatigue and seizures. According to literature, 
Cpt1cgt/gt mice have a low food intake and this might be the cause of 
their lower body weight. Our group however, obtained opposite 
results: Cpt1cgt/gt mice have the same food intake and activity rate if 
compared with WT mice, but have higher energy expenditure (EE). 
This higher EE rate might be the cause of the lean phenotype. 
Conclusions: Our results indicate that Cpt1c expression in the 
Nf1+/:p53+/- mice might contribute to a more malignant phenotype of 
cancer cells. Nf1+/-:p53+/-:Cpt1cgt/gt developed tumors less frequently 
and had a higher survival rate. However, they showed a cachectic 
phenotype that still needs to be elucidated.Cpt1c-deficient mice have 
a lower body weight and higher EE rate if compared to WT mice. We 
hypothesize that tumor cells lacking Cpt1c suffer from insufficient 
nutrient supply which may cause the delay in tumor growth. 
Understanding how Cpt1c expression influences cancer cells might 
give new insights for the prediction of therapy efficiency and 
furthermore may lead to novel therapeutic approaches. Cpt1c is a 
potential target for the treatment of hypoxia- and radiation-resistant 
tumors. 
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Purpose/Objective: Medulloblastoma is one of the most common 
childhood brain malignancies. The purpose of this study is to evaluate 
the tolerability and prognostic factors for toxicity of craniospinal 
irradiation (CSI) with helical tomotherapy (HT) in the treatment of 
medulloblastoma. 
Materials and Methods: The institutional review board approved a 
retrospective chart review, which was conducted for pediatric 
patients with primary medulloblastoma treated with craniospinal HT 
from May 2007 through December 2010. Inclusion criteria were having 
a primary diagnosis of medulloblastoma, no prior history of RT, age < 
18 years old, and having a minimum follow up of 6 months for living 
patients. We found 19 patients (standard risk, N=10; high risk, N=9) 
who met such criteria. HT regimens to the neuroaxis included: 23.4 Gy 
at 1.8 Gy/fraction (N=10), 36 Gy at 1.8 Gy/fraction (N=7), and 39 Gy 
bid at 1.3 Gy/fraction (N=2). The tumor bed received 54-60 Gy at 1.5-
1.8 Gy/fraction. Toxicity was scored using the Radiation Therapy 
Oncology Group scoring system. These groups were divided according 
the toxicity location as follows: overall toxicity, cranial toxicity 
(defined as any non-hematological toxicity experienced above the 
neck), body toxicity (defined as any non-hematological toxicity 
experienced below the neck), and hematological toxicity. Spearman's 
rank correlation coefficient was used to correlate patient, tumor, and 
dosimetric factors with the grade of acute toxicity or the overall 
survival time. 
Results: The median age at diagnosis was 5 years (range, 2-14) and 
the median follow-up for living patients (N=14) was 40 months (range, 
10-62). Two and three-year overall survival was 75% and 68%, 
respectively. Only 2 patients had a local failure in the surgical bed. 
The most common acute toxicity was hematological (79%), being 
grade 2 and grade 3 in 4 (21%) and 11 (58%) cases, respectively. 
Specifically, grade 3 acute anemia, neutropenia, and thrombopenia 
was observed in 5% (N=1), 53% (N=10), and 10% (N=2), respectively. In 
addition, there were two cases of grade 2 skin toxicity, seven cases of 
grade 2 upper gastrointestinal toxicity, and one case of grade 2 
pharynx toxicity. There were no cases of grade 4 acute toxicity. No 
grade ≥2 late toxicities were observed. A longer time between 
diagnosis and radiation therapy associated with shorter overall 
survival (P =0.03). Older children were associated with higher grades 
of acute body toxicity (P =0.004), whereas longer radiation treatments 
associated with higher grades of acute hematological toxicity (P 
=0.034). 
Conclusions: Although the follow-up is relatively short, clinical 
outcomes of CSI schedule with HT are favorable, resulting in lower 
doses to the normal tissue. Acute and late toxicities are tolerable 
without severe late side effects. Further research is necessary to 
assess longer late toxicity and tumor control outcomes.  
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Purpose/Objective: To evaluate the risk of FDG-PET/CT (Positron 
Emission Tomography/Computed Tomography) scanning of paediatric 
patients in terms of radiation-induced secondary cancers. The risk of 
cancer induction was estimated and the resulting reduction of life 
expectancy was compared to the life years lost (LYL) attributable to 
the cancer therapy. 
Materials and Methods: Forty paediatric cancer patients (≤18 years 
old) with a FDG-PET/CT-scan performed between 2004 and 2012 were 
included in the study. The majority of the malignancies were 
lymphomas and sarcomas. Patient-specific information regarding the 
PET/CT scans was extracted from clinical records. For seventeen 
patients, radiotherapy plans (RTPs) were made on CT-data from a 
different scan and that additional dose was included in the risk 
estimation for the combined diagnostics.  The effective doses (EDs) 
from the FDG-PET scans were estimated using the conversion factors 
reported in ICRP 106. The EDs from the CT scans were assessed using a 
commercially available spreadsheet-based software with Monte Carlo 
simulated dose data. The risk of solid cancer induction was estimated 
according to the risk models presented in the BEIR VII report. The risk 
estimates formed the basis for estimating the lifetime attributable 
risk (LAR) of developing a solid cancer. The LAR was used with the 
cancer prognosis to estimate the LYL compared to the general 
population.  
Results: The mean estimated LAR of developing solid cancer due to 
the diagnostic scans was 0.42% (median: 0.37%, range: 0.12-1.30%) for 
the whole population. For the female and male groups, the LAR was 
0.50% (median: 0.43%, range: 0.29-1.30% and 0.34% (median: 0.33%, 
range: 0.12-0.75%), respectively. 
The effective doses are presented in table 1 and figure 1a.  
The LYL attributable to late effects from cancer therapy was 
estimated to 5.0 years and 3.7 years for females and males, 
respectively (derived from data in a report on excess mortality on 
patients in the childhood cancer survivor study). The ratios of 
attributable LYL for diagnostic scans and cancer therapy were <3%, 
see figure 1b. 
 
 Mean Median Range Total effective dose 
Diagnostic scans 
Females 
35.24 mSv 34.3 mSv 13.0-90.1 mSv 
Total effective dose 
Diagnostic scans 
Males 
42.1 mSv 39.1 mSv 12.3-78.1 mSv 
% of total effective dose 
from 18F-FDG-PET 
Females 
25.8% 21.3% 8.6-63.1% 
% of total effective dose 
from 18F-FDG-PET 
Males 
23.1% 21.2% 6.2-63.0% 
Table 1: Effective Doses. 
 
 
